Risk of Drug-Drug Interactions in Patients With HIV and Cancer
As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.
As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.
Men in highest quintile of plant-based dietary index had significantly lower risk for prostate cancer progression and recurrence.
Implementation of on-site guideline-based genetic testing for prostate cancer patients increased compliance from 33.3% to 98.7%.
Experts are calling on colleagues to bring up the cost of care and its potential impact when discussing treatment options with patients.
However, there were no statistically significant changes in rates by race.
The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated genes.
Researchers used 2018 data from the National Health Interview Survey to investigate the association.
Equal access to care may not be sufficient to eliminate racial and ethnic disparities in prostate cancer care, according to investigators.
A study of patients with localized prostate cancer showed that 13% reported treatment-related regret.
Finding from a recent study could be used in patient counseling to promote healthier lifestyle choices to reduce the likelihood of prostate biopsy, according to investigators.